The role of FBXO22 as a tumor driver is supported by the frequent overexpression of this protein in cancer, and by xenograft models, where FBXO22 expression promotes tumorigenesis by degradation of nuclear PTEN [77]. The gene discussed is PTEN; the disease is cancer.